Invent Medic Sweden (IMS) Q2 2025 earnings summary

Executive summary

• Improved results, strengthened equity ratio, and increased sales of Efemia Bladder Support compared to Q2 2024.

• Net loss reduced by 600 KSEK year-over-year for H1 2025, with halved short-term liabilities and improved financial position.

• Strong sales momentum in France and NHS inclusion in the UK, expanding market reach.

• Continued efficiency improvements and reduced personnel costs support long-term growth.

Financial highlights

• Q2 2025 net revenue: 1,829 KSEK (vs. 1,952 KSEK Q2 2024); H1 2025: 3,830 KSEK (vs. 3,807 KSEK H1 2024).

• Q2 2025 pre-tax result: -1,539 KSEK (vs. -1,665 KSEK Q2 2024); H1 2025: -2,939 KSEK (vs. -3,591 KSEK H1 2024).

• EPS Q2 2025: -0.01 SEK (vs. -0.04 SEK Q2 2024); H1 2025: -0.03 SEK (vs. -0.08 SEK H1 2024).

• Cash and equivalents at June 30: 2,662 KSEK (vs. 1,217 KSEK prior year).

• Total cash flow for H1 2025: 1,415 KSEK (vs. -330 KSEK H1 2024).

Outlook and guidance

• Focus remains on public procurement and prescription markets for Efemia, with expansion into consumer-driven markets.

• Strengthened financial position and growing partnerships position the company for the next growth phase.